Methanol extract of the ethnopharmaceutical remedy Smilax spinosa exhibits anti-neoplastic activity

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1164-1172

  Seelinger, Mareike ^a   Popescu, Ruxandra ^b   Giessrigl, Benedikt ^a   Jarukamjorn, Kanokwan ^b,c   Unger, Christine ^a   Wallnöfer, Bruno ^d   Fritzer Szekeres, Monika ^a   Szekeres, Thomas ^a   Diaz, Rene ^e   Jäger, Walter ^b   Frisch, Richard ^e   Kopp, Brigitte ^b   Krupitza, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c KHON KAEN UNIVERSITY   (Thailand)

^d NATURHISTORISCHES MUSEUM WIEN   (Austria)

^e Institute for Ethnobiology   (Guatemala)

Author keywords

Apoptosis; c Myc; Proto oncogenes; Smilax spinosa; Stat3

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME P450 1A1; ESTROGEN RECEPTOR; METHANOL; PLANT EXTRACT; PROTEIN P21; SMILAX SPINOSA EXTRACT; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FRACTIONATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RHIZOME; SARSAPARILLA; SMILAX SPINOSA; TRADITIONAL MEDICINE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CASPASE 8; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; FEMALE; HL-60 CELLS; HUMANS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PHYTOTHERAPY; PLANT EXTRACTS; SMILAX; STAT3 TRANSCRIPTION FACTOR;

EID: 84865037063     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1538     Document Type: Article

References (48)

1. Pecorino L: Molecular Biology of Cancer. 2nd edition. Oxford University Press, New York, NY, 2008.
2. Stewart BW and Kleihues P: World Cancer Report. IARC Press, Lyon, 2003.
3. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005. (Pubitemid 41073525)
4. Fabricant DS and Farnsworth NR: The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 109: 69-75, 2001. (Pubitemid 32303231)
5. Rastogi RP and Dhawan BN: Research on medicinal plants at the Central Drug Research Institute, Lucknow (India). Indian J Med Res 76: 27-45, 1982. (Pubitemid 13102724)
6. Cseke LJ: Natural products from plants. 2nd edition. CRC Press Taylor and Francis, Boca Raton, FL, 2006.
7. Shoeb M: Anticancer agents from medicinal plants. Bangladesh J Pharmacol 1: 35-41, 2006.
8. Kundu JK and Surh YJ: Inflammation: gearing the journey to cancer. Mutat Res 659: 15-30, 2008.
9. Taylor L: The Healing Power of Rainforest Herbs: A Guide to Understanding and Using Herbal Medicinals. Square One Publishers, New York, NY, 2005.
10. Caceres A, Cano O, Samayoa B and Aguilar L: Plants used in Guatemala for the treatment of gastrointestinal disorders. 1. Screening of 84 plants against enterobacteria. J Ethnopharmacol 30: 55-73, 1990. (Pubitemid 20255023)
11. Jiang J and Xu Q: Immunomodulatory activity of the aqueous extract from rhizome of Smilax glabra in the later phase of adjuvant-induced arthritis in rats. J Ethnopharmacol 85: 53-59, 2003. (Pubitemid 36170056)
12. Alam MI and Gomes A: Adjuvant effects and antiserum action potentiation by a (herbal) compound 2-hydroxy-4-methoxy benzoic acid isolated from the root extract of the Indian medicinal plant 'sarsaparilla' (Hemidesmus indicus R. Br.). Toxicon 36: 1423-1431, 1998. (Pubitemid 28352733)
13. Navarro MC, Montilla MP, Cabo MM, Galisteo M, Cáceres A, Morales C and Berger I: Antibacterial, antiprotozoal and antioxidant activity of five plants used in Ibazal for infectious. Phytother Res 17: 325-329, 2003. (Pubitemid 36565335)
14. Arvigo R and Balick M: Rainforest Remedies. One Hundred Healing Herbs of Belize. 2nd edition, Lotus Press, Twin Lakes, WI, pp72-73, 1998.
15. Gridling M, Stark N, Madlener S, Lackner A, Popescu R, Benedek B, Diaz R, Tut FM, Nha Vo TP, Huber D, et al: In vitro anti-cancer activity of two ethno-pharmacological healing plants from Guatemala Pluchea odorata and Phlebodium decumanum. Int J Oncol 34: 1117-1128, 2009.
16. Stark N, Gridling M, Madlener S, Bauer S, Lackner A, Popescu R, Diaz R, Tut FM, Vo TP, Vonach C, et al: A polar extract of the Maya healing plant Anthurium schlechtendalii (Aracea) exhibits strong in vitro anticancer activity. Int J Mol Med 24: 513-521, 2009.
17. Strasser S, Maier S, Leisser C, Saiko P, Madlener S, Bader Y, Bernhaus A, Gueorguieva M, Richter S, R. Mader RM, et al: 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC- resistant MCF-7 breast cancer cells overexpressing ErbB2. Differentiation 74: 488-498, 2006. (Pubitemid 44922494)
18. Maier S, Strasser S, Saiko P, Leisser C, Sasgary S, Grusch M, Madlener S, Bader Y, Hartmann J, Schott H, et al: Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC. Apoptosis 11: 427-440, 2006.
19. Hüttenbrenner S, Maier S, Leisser C, Polgar D, Strasser S, Grusch M and Krupitza G: The evolution of cell death programs as prerequisites of multicellularity. Rev Mutat Res 543: 235-249, 2003. (Pubitemid 36645082)
20. Grusch M, Fritzer-Szekeres M, FuhrmannG, Rosenberger G, Luxbacher C, Elford HL, Smid K, Peters GJ, Szekeres T and Krupitza G: Activation of caspases and induction of apoptosis by amidox and didox. Exp Haematol 29: 623-632, 2001.
21. Madlener S, Rosner M, Krieger S, Giessrigl B, Gridling M, Vo TP, Leisser C, Lackner A, Raab I, Grusch M, et al: Short 42 degrees C heat shock induces phosphorylation and degradation of Cdc25A which depends on p38MAPK, Chk2 and 14.3.3. Hum Mol Genet 18: 1990-2000, 2009.
22. Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature 432: 316-323, 2004. (Pubitemid 39551659)
23. Blomberg I and Hoffmann I: Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol Cell Biol 19: 6183-6194, 1999. (Pubitemid 29399323)
24. Kiyokawa H and Ray D: In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med Chem 8: 832-836, 2008.
25. Meeran SM and Katiyar SK: Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 13: 2191-2202, 2008. (Pubitemid 351589245)
26. Wolf D and Rotter V: Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82: 790-794, 1985. (Pubitemid 15142764)
27. Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistanc. Expert Rev Mol Med 10: e19, 2008.
28. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN and Golub TR: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Sci USA 97: 3260-3265, 2000. (Pubitemid 30183289)
29. Chang C, Zhu YQ, Mei JJ, Liu SQ and Luo J: Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells. J Exp Clin Cancer Res 29: 145-154, 2010.
30. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M and Bonner WM: A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10: 886-895, 2000. (Pubitemid 30647617)
31. Piperno G, LeDizet M and Chang J: Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 104: 289-302, 1987.
32. Jackson CB and Giraud AS: Stat3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol 24: 505-507, 2009.
33. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, et al: Stat3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004. (Pubitemid 38932164)
34. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19, 2006. (Pubitemid 43166170)
35. Deng JY, Sun D, Liu XY, Pan Y and Liang H: Stat-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 16: 5380-5387, 2010.
36. Zhao M, Jiang B and Gao FH: Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 18: 4012-4018, 2011.
37. Gündogdu MS, Liu H, Metzdorf D, Hildebrand D, Aigner M, Aktories K, Heeg K and Kubatzky KF: The haematopoietic GTPase RhoH modulates IL3 signalling through regulation of Stat activity and IL3 receptor expression. Mol Cancer 9: 225-238, 2010.
38. Jinawath N, Va,soontara C, Jinawath A, Fang X, Zhao K, Yap KL, Guo T, Lee CS, Wang W, Balgley BM, et al: Oncoproteomic analysis reveals co-upregulation of RELA and Stat5 in carboplatin resistant ovarian carcinoma. PLoS One 5: e11198, 2010.
39. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J and Dalla-Favera R: Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451, 2007. (Pubitemid 47123512)
40. Wang H, Birkenbach M and Hart J: Expression of Jun family members in human colorectal adenocarcinoma. Carcinogenesis 21: 1313-1317, 2000. (Pubitemid 30455989)
41. Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, Daugaard M, Valo E, Tuomela S, Bøttzauw T, et al: Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 31: 390-401, 2012.
42. Ivanova A, Mikhova B, Klaiber I, Dinchev D and Kostova I: Steroidal saponins from Smilax excelsa rhizomes. Nat Prod Res 23: 916-924, 2009.
43. Doyle BJ, Frasor J, Bellows LE, Locklear TD, Perez A, Gomez-Laurito J and Mahady GB: Estrogenic effects of herbal medicines from Costa Rica used for the management of menopausal symptoms. Menopause 16: 748-755, 2009.
44. Yu Z, Hu D and, Li Y: Effects of zearalenone on mRNA expression and activity of cytochrome P450 1A1 and 1B1 in MCF-7 cells. Ecotoxicol Environ Saf 58: 187-193, 2004. (Pubitemid 38638534)
45. Sergentanis TN and Economopoulos KP: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122: 459-469, 2010.
46. Sergentanis TN and Economopoulos KP: Erratum to: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 131: 1083, 2012.
47. Kozak W, Mayfield KP, Kozak A and Kluger MJ: Proadifen (SKF-525A), an inhibitor of cytochrome P-450, augments LPS-induced fever and exacerbates prostaglandin-E2 levels in the rat. J Therm Biol 25: 45-50, 2000. (Pubitemid 30063193)
48. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS and Liao JK: Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 90: 1020-1027, 2002. (Pubitemid 34633869)